OrbiMed and Third Rock’s Terremoto Biosciences raises $175M for small molecule R&D
02 Nov 2023
IPO
Terremoto Biosciences has reeled in $175 million to create small molecules based on work from Principia Biopharma co-founder Jack Taunton and Global Blood Therapeutics co-founder Matthew Jacobson.
The Series B arrives 18 months after the South San Francisco biotech emerged with $75 million from OrbiMed and Third Rock Ventures. Thursday’s financing is another sign that Third Rock is doubling down on select companies in its portfolio, with Rapport Therapeutics bagging two nine-figure rounds this year and CARGO Therapeutics planning an IPO less than 12 months after its big unveiling.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
-Targets
-Drugs
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.